R/data.R

In brendalewisprice/IPCWTMLE2Phase: Inverse Probability of Censoring Weighted Targeted Minimum Loss-based Estimation for Two-Phase STudies

#' Simulated CYD14 Two-Phase Data Set
#'
#' Data simulated to mimic the CYD14 Tetravalent Dengue Vaccine Trial conducted by Sanofi-Pasteur
#'
#' @docType data
#'
#' @usage data(simCYD14_twostage)
#'
#' @format A data frame simulated to mimic a phase 3 dengue vaccine efficacy trial with 10250 rows and the following 40 variables:
#' \describe{
#'   \item{X}{Row number}
#'   \item{STUDYID}{Study name}
#'   \item{SUBJID}{Subject ID}
#'   \item{VACC}{Vaccination status: vaccine=1; placebo=0}
#'   \item{AGEYRS}{Subject age at enrollment}
#'   \item{SEX}{M=male; F=female}
#'   \item{Male}{Binary indicator: 1=male, 0=female}
#'   \item{COUNTRY}{Country code}
#'   \item{IDN-MEX}{Country code indicator variables}
#'   \item{VCD}{Any VCD (virally confirmed dengue)=1, no VCD=0}
#'   \item{VCD_Sero1-VCD_Sero4}{Indicator of VCD specific serotype 1 - serotype 4}
#'   \item{baseline_PRNT_Sero1-baseline_PRNT_Sero4}{Baseline serotype PRNT titers for serotypes 1-4}
#'   \item{baseline_PRNT_SeroAverage}{Geometric mean of baseline PRNT titers}
#'   \item{M13_PRNT_Sero1-M13_PRNT_Sero4}{M13 serotype PRNT titers for serotypes 1-4}
#'   \item{M13_PRNT_SeroAverage}{Geometric mean of M13 PRNT titers}
#'   \item{M13_MNv2_Sero1-M13_MNv2_Sero4}{M13 serotype MNv2 titers for serotypes 1-4}
#'   \item{M13_MNv2_SeroAverage}{Geometric mean of M13 MNv2 titers}
#'   \item{weight}{Observation level sampling weight for sampling to phase-two}
#'   \item{delta}{Indicator of sampling to phase-two sample}
#' }
#' @keywords datasets
#'
#' @references Capeding et al. (2014) The Lancet 384:1358--1365
"simCYD14_twostage"


#' Simulated CYD15 Two-Phase Data Set
#'
#' Data simulated to mimic the CYD15 Tetravalent Dengue Vaccine Trial conducted by Sanofi-Pasteur
#'
#' @docType data
#'
#' @usage data(simCYD15_twostage)
#'
#' @format A data frame simulated to mimic a phase 3 dengue vaccine efficacy trial with 20500 rows and the following 40 variables:
#' \describe{
#'   \item{X}{Row number}
#'   \item{STUDYID}{Study name}
#'   \item{SUBJID}{Subject ID}
#'   \item{VACC}{Vaccination status: vaccine=1; placebo=0}
#'   \item{AGEYRS}{Subject age at enrollment}
#'   \item{SEX}{M=male; F=female}
#'   \item{Male}{Binary indicator: 1=male, 0=female}
#'   \item{COUNTRY}{Country code}
#'   \item{IDN-MEX}{Country code indicator variables}
#'   \item{VCD}{Any VCD (virally confirmed dengue)=1, no VCD=0}
#'   \item{VCD_Sero1-VCD_Sero4}{Indicator of VCD specific serotype 1 - serotype 4}
#'   \item{baseline_PRNT_Sero1-baseline_PRNT_Sero4}{Baseline serotype PRNT titers for serotypes 1-4}
#'   \item{baseline_PRNT_SeroAverage}{Geometric mean of baseline PRNT titers}
#'   \item{M13_PRNT_Sero1-M13_PRNT_Sero4}{M13 serotype PRNT titers for serotypes 1-4}
#'   \item{M13_PRNT_SeroAverage}{Geometric mean of M13 PRNT titers}
#'   \item{M13_MNv2_Sero1-M13_MNv2_Sero4}{M13 serotype MNv2 titers for serotypes 1-4}
#'   \item{M13_MNv2_SeroAverage}{Geometric mean of M13 MNv2 titers}
#'   \item{weight}{Observation level sampling weight for sampling to phase-two}
#'   \item{delta}{Indicator of sampling to phase-two sample}
#'
#' }#'
#' @keywords datasets
#'
#' @references Villar et al. (2015) New England Journal of Medicine 372:112-123
"simCYD15_twostage"